Back to search results

Knee Osteoarthritis Treatment with Zilretta vs. Kenalog in Type 2 Diabetes

This study is looking at how two different knee injections, Zilretta (triamcinolone acetonide extended-release) and Kenalog (triamcinolone acetonide immediate-release), affect blood sugar levels in people with knee osteoarthritis and Type 2 diabetes. You might be able to join if you are at least 40 years old, have Type 2 diabetes that is not managed with insulin (HbA1C ≤9), and have knee osteoarthritis. The main goal is to see how much time participants spend with blood glucose (blood sugar) levels above 180 mg/dL in the 72 hours after treatment. The current recruitment status is unclear.

Study design
This is a randomized, double-blind study comparing two treatments in about 120 participants.
What's involved
Your total participation in the study will be about 4 months, including screening, a pre-treatment phase, the treatment day, and a 12-week post-treatment period.
Compensation
Not stated in the trial record.
Follow-up
Your blood glucose will be measured for up to 72 hours after treatment, and you will be followed for 12 weeks post-treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06478186

Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes

Recruiting
PHASE4Ages 40+InterventionalTreatment
University of Kansas Medical Center
~120 participants
Updated 2026-05-28 on ClinicalTrials.gov
What's tested:triamcinolone acetonide extended-release injectable suspension; TCA-ERTriamcinolone Acetonide- Immediate Release;TCA-IR

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent of time spent with blood glucose >180 mg/dL
Measured over The primary outcome will be measured up to 72 hours after treatment by a sensor automatically uploading the data

Conditions

Osteoarthritis, Knee
Diabetes Mellitus, Type 2

Explore related trials

OsteoarthritisType 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Kansas1

Study leadership

  • Neil A Segal, MD, MS · PRINCIPAL_INVESTIGATOR · University of Kansas Medical Center

Who to contact

Jeannine Nilges, MD
[email protected]
913-574-0961
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

1\. Written consent to participate in the study. 2. Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions.
Stiffness \<30 minutes
Crepitus 3. Osteophytes 12. Index knee pain more than 15 days over the last month (as reported by the subject).

What this trial measures

  • Percent of time spent with blood glucose >180 mg/dLThe primary outcome will be measured up to 72 hours after treatment by a sensor automatically uploading the data

    To assess continuous glucose monitoring (CGM) patterns for Time Above Range (TAR) levels of the upper limit of the recommended target range (glucose levels \>180 mg/dL) from Baseline to 72 hours following a single IA injection of 32 mg of ZILRETTA relative to 40 mg of TA-IR.